This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Immunomedics Develops New Bispecific Antibodies That Exhibit Potent Anti-Lymphoma Activity

Stocks in this article: IMMU

-- Two Preclinical Studies Presented at the 54th Annual Meeting of the American Society of Hematology (ASH) -- -- Preclinical Study of Milatuzumab in Graft-Versus-Host Disease also Presented --

ATLANTA, Dec. 12, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that two new classes of bispecific antibodies were created as the DOCK-AND-LOCK™ (DNL™) complexes using the Company's patented platform technology that enables site-specific conjugation of two self-assembling modules. These bispecific antibodies exhibited potent cell killing activity against lymphoma cell lines in vitro.

Antibodies are large Y-shaped proteins, comprising two identical target-binding arms, each referred to as the fragment, antigen binding (Fab) region, and a tail known as the fragment crystalline (Fc) region. When an antibody is bound to its target via the two Fab arms, interaction of the Fc region with the Fc receptors on blood cells may result in eliminating the tagged target. Other mechanisms of target killing can be achieved with engineered antibodies of various designs, often with enhanced potency compared to the parental antibodies.

Redirecting T cells with a Novel Class of DNL TM Complexes

One advance that the Company presented at the 2012 ASH Annual Meeting is a novel T-cell redirecting agent made as a DNL TM complex by tethering a pair of Fabs that recognize CD19 on B cells to a single-chain variable fragment (scFv) that binds to CD3 on T cells. Referred to as (19)-3s, the prototype potently directs T cells to destroy CD19-expressing B cells by linking them together. Specifically, (19)-3s was shown to bind to T cells and non-Hodgkin lymphoma (NHL) cells simultaneously, and induce T-cell-mediated killing of NHL cells at less than 1 picomolar (pM) concentrations in an ex vivo setting, with maximal activity at 10 pM.

"We expect (19)-3s to have an elimination rate longer than that of blinatumomab, which is made of two scFvs to co-ligate CD19 and CD3," commented Cynthia L. Sullivan, President and Chief Executive Officer. "We are currently evaluating the in vivo activity of (19)-3s, as a prototype, to determine if this novel bsAb offers additional advantages," Ms. Sullivan added. "The slower clearance and the fact that (19)-3s has two binding arms might allow for less frequent dosing, and possibly subcutaneous administration. The modular nature of DNL will allow the rapid production of a large number of related conjugates for redirected T-cell killing of various malignancies, without the need for additional recombinant engineering and protein production," concluded Ms. Sullivan.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs